Researchers at Mount Sinai School of Medicine have developed a new gene¹ therapy that is safe and effective in reversing advanced heart failure. SERCA2a (produced as MYDICAR®) is a gene therapy designed to stimulate²（刺激，鼓励） production of an enzyme³（酶） that enables the failing heart to pump more effectively. In a Phase II study, SERCA2a injection through a routine minimally⁴ invasive cardiac catheterization（心导管插入术） was safe and showed clinical benefit in treating this patient population and decreasing the severity（严格，猛烈） of heart failure. The data were presented this week at the Heart Failure Congress of the European Society of Cardiology in Berlin. "SERCA2a met the primary endpoints and appears to be safe and effective in people with advanced heart failure," said trial investigator⁵ Jill Kalman, MD, Associate Professor, Medicine, Cardiology, Director of the Cardiomyopathy Program, Mount Sinai School of Medicine. "There is a significant unmet need for treatments in this patient population, and these data indicate that SERCA2a is a promising⁶ option for them."

The CUPID (Calcium Up-regulation by Percutaneous administration of gene therapy In cardiac Disease) trial is a randomized（随机的） , double-blind, placebo⁷-controlled study, which enrolled⁸ 39 patients with advanced heart failure to study the safety and efficacy of SERCA2a. Patients were randomized to receive SERCA2a gene delivery in one of three doses or placebo（安慰剂，对照剂） and were evaluated over six months. The treatment is delivered directly to the patient's heart during a routine outpatient（门诊病人） catheterization（导管插入） procedure.

Patients in the SERCA2a group demonstrated improvement or stabilization⁹ in symptoms, heart function, and severity of heart failure. They also saw an increase in time between cardiovascular（心血管的） events and a decrease in frequency of events. SERCA2a was found to be safe, with no increases in adverse¹⁰ events, disease-related events, laboratory abnormalities, or arrhythmias（心率不齐） compared to placebo.

SERCA2a was developed by a team led by Roger J. Hajjar, MD, Research Director of Mount Sinai's Wiener Family Cardiovascular Research Laboratories and the Arthur & Janet Ross Professor of Cardiology, Medicine, and Gene and Cell Medicine, Mount Sinai School of Medicine. The team discovered the landmark¹¹ potential of the treatment in 1999 and has been pursuing its potential as a gene therapy target in state-of-the-art specially¹² built pre-clinical laboratories at Mount Sinai.

"Mount Sinai Heart is committed to developing ground-breaking therapies and bringing them from bench to bedside," said Valentin Fuster, MD, Director of Mount Sinai Heart, the Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josee and Henry R. Kravis Center for Cardiovascular Health, The Mount Sinai Medical Center. "We look forward to further study of this important treatment."

According to the U.S. Centers for Disease Control & Prevention, about 5.8 million Americans suffer from heart failure, and 670,000 new cases are diagnosed each year. One in five people who have heart failure die within one year of diagnosis¹³. In 2010, heart failure will cost the United States $39.2 billion, including the cost of health care services, medications（药物治疗） , and lost productivity. Heart failure is most often treated with aggressive medical and device therapy, but has no cure. The most common symptoms of heart failure are shortness of breath, feeling tired, and swelling¹⁴（肿胀） in the ankles, feet, legs, and sometimes the abdomen¹⁵（腹部） .